GSK 3359609

Drug Profile

GSK 3359609

Alternative Names: GSK3359609

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Inducible T-cell co-stimulator protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 30 Jun 2016 Phase-I clinical trials in Solid tumours in Canada (IV) (NCT02723955; 9198913)
  • 04 Apr 2016 GlaxoSmithKline plans a first-in-human phase I trial for Solid tumours (Combination therapy, Monotherapy, Second-line therapy or greater, Late-stage disease, Metastatic disease, Recurrent) in USA, Canada and Australia (IV) (NCT02723955)
  • 24 Mar 2016 Preclinical trials in Solid tumours in Canada (IV) (NCT02723955)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top